Equipment to Support Prophylactic Antibacterial Vaccine Development

Absynth正在开发预防细菌感染的疫苗，以应对抗菌素耐药性（AMR）的挑战。疫苗很重要，因为预防感染将直接减少对抗生素的需求。此外，此类预防性疫苗从未显示出诱导抗性。Absynth的研发重点是针对感染性细菌金黄色葡萄球菌和艰难梭菌的疫苗-由于这些病原体造成的损害和死亡，对公共卫生至关重要。Absynth能够与竞争对手竞争，因为它拥有一套新的蛋白质疫苗抗原，这些抗原与竞争对手的产品不同，并可能提供优于竞争对手的优势。Absynth正在寻求一笔赠款，用于购买价值9.5万英镑的设备，用于其研发项目。最初Absynth租赁二手设备，但三年后，关键设备越来越不可靠，影响了Absynth开展工作的能力。这项投资对Absynth和纳税人来说都是物有所值的，因为使用新设备，该公司将推进S。金黄色葡萄球菌疫苗的阶段，它已经获得了合作伙伴，将资助临床前安全性研究和临床试验，通过市场。

Absynth is developing vaccines to prevent bacterial infections to address the challenge of antimicrobial resistance (AMR). Vaccines are important as prevention of infections will directly reduce the need for antibiotics. Also such prophylactic vaccines have never been shown to induce resistance. Absynth’s R&D focuses on vaccines against the infectious bacteria Staphylococcus aureus and Clostridium difficile - important to public health because of the damage and death caused by these pathogens. Absynth is able to compete against the competition because it has a suite of novel protein vaccine antigens that differ from and potentially offer benefits over competitor products. Absynth is seeking a grant to purchase equipment costing £95,000, for use in its R&D programmes. Originally Absynth leased second-hand equipment but after three years key pieces of equipment are increasingly unreliable, impacting Absynth’s ability to carry out its work. The investment is good value for money for Absynth and the taxpayer as using the new equipment the company will advance the S. aureus vaccine to the stage where the partner it has already secured, will fund preclinical safety studies and clinical trials through to market.